文献速递鼻科

LYR-220 莫米松鼻窦植入物在慢性鼻窦炎伴筛窦手术史患者中的评估:随机盲法对照 BEACON 2 期研究结果

Evaluation of LYR-220 Mometasone Sinonasal Implants in Patients With Chronic Rhinosinusitis and Prior Ethmoid Surgery: Results From the Randomized, Blinded, Controlled BEACON Phase 2 Study.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-03-18

BEACON 2 期研究纳入 42 例有内镜鼻窦手术史的慢性鼻窦炎成人,随机接受 LYR-220 或假手术。主要终点为治疗相关严重不良事件,结果无严重不良事件报告。LYR-220 组自第 2 周起 SNOT-22 显著改善,第 24 周组间差 -16.8(p=0.007),3CS 组间差 -1.50(p=0.02),筛窦浑浊百分比体积组间差 -8.14(p=0.035)。

要点

  • BEACON 2 期研究显示 LYR-220 在既往接受 ESS 的 CRS 患者中未报告严重不良事件
  • 第 24 周 SNOT-22 组间差 -16.8(p=0.007),LYR-220 优于假手术
  • 第 24 周 3CS 组间差 -1.50(p=0.02),筛窦浑浊百分比体积组间差 -8.14(p=0.035)

核心结论

  • BEACON 研究显示 LYR-220 在既往接受内镜鼻窦手术的慢性鼻窦炎患者中具有安全性、有效性、可行性和耐受性。
  • 主要终点达到,研究期间未报告严重不良事件。
  • LYR-220 在关键症状性和客观有效性终点上显示出统计学显著且临床相关的改善。

研究设计与样本

  • 多中心、随机、对照 2 期 BEACON 研究,纳入 42 例有慢性鼻窦炎且既往接受内镜鼻窦手术的成人。
  • 患者双侧接受 LYR-220 或假手术操作。
  • 主要终点为任何治疗相关严重不良事件的发生。

主要发现

  • 研究期间未报告严重不良事件。
  • SNOT-22 评分自第 2 周起 LYR-220 较假手术显著改善,第 24 周组间差 -16.8(p=0.007)。
  • 第 24 周 3CS 组间差 -1.50(p=0.02),筛窦浑浊百分比体积组间差 -8.14(p=0.035)。
  • LYR-220 组 5 例、假手术组 7 例使用全身 corticosteroids(SCS)。
  • 嗅觉丧失从第 8 周至 24 周治疗结束 LYR-220 较假手术改善(-0.87,p=0.026)。

关键数值与推荐

  • 主要终点为治疗相关严重不良事件发生,研究期间未报告严重不良事件。
  • 第 24 周 SNOT-22 组间差 -16.8(p=0.007),LYR-220 优于假手术。
  • 第 24 周 3CS 组间差 -1.50(p=0.02),LYR-220 优于假手术。
  • 第 24 周筛窦浑浊百分比体积组间差 -8.14(p=0.035),LYR-220 优于假手术。
  • 第 8 周至 24 周嗅觉丧失组间差 -0.87(p=0.026),LYR-220 优于假手术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic sinus surgery (ESS) often fails to directly manage the underlying inflammation in chronic rhinosinusitis (CRS), resulting in symptom recurrence in a significant number of patients. LYR-220 is a long-acting (24-week) corticosteroid sinonasal implant being developed for treatment of these patients. METHODS: Forty-two adults with CRS and prior ESS were enrolled in the multicenter, randomized, controlled Phase 2 (BEACON) study. Patients received LYR-220 or a sham procedure bilaterally. The primary endpoint was occurrence of any treatment-related serious adverse events (SAEs). Efficacy endpoints included change from baseline (CFBL) in Sino-Nasal Outcome Test (SNOT-22); three cardinal symptoms (3CS) of CRS (nasal blockage, nasal discharge, and facial pain/pressure); loss-of-smell; ethmoid percent opacification volume; and need for rescue treatment (systemic corticosteroids [SCS] or sinonasal surgery). RESULTS: No SAEs were reported in the study. SNOT-22 scores significantly improved with LYR-220 versus sham from week 2 onwards, with a between group difference of -16.8 at Week 24 (p = 0.007). Between group difference at Week 24 for 3CS was -1.50 (p = 0.02) and for ethmoid percent opacification volume was -8.14 (p = 0.035). Five patients from LYR-220 group and seven from sham group used SCS. LYR-220 showed improvement versus sham in the loss-of-smell from Week 8 through the end of treatment at 24 weeks (-0.87, p = 0.026). CONCLUSIONS: The BEACON study demonstrated safety, efficacy, feasibility, and tolerability of LYR-220 in patients with CRS who have had prior ESS. The primary endpoint was met, with no SAEs reported. LYR-220 demonstrated statistically significant, clinically relevant improvements in key symptomatic and objective efficacy endpoints.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Senior BA, Ow RA, Major MS, et al. Evaluation of LYR-220 Mometasone Sinonasal Implants in Patients With Chronic Rhinosinusitis and Prior Ethmoid Surgery: Results From the Randomized, Blinded, Controlled BEACON Phase 2 Study. Int Forum Allergy Rhinol. 2025. PMID: 40099952. doi:10.1002/alr.23567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。